CLDX Celldex Therapeutics Inc

Price (delayed)

$47.96

Market cap

$2.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.7

Enterprise value

$2.19B

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which ...

Highlights
Celldex Therapeutics's revenue has soared by 96% YoY and by 60% from the previous quarter
The company's gross profit has surged by 96% YoY and by 60% QoQ
CLDX's quick ratio is down by 41% year-on-year but it is up by 8% since the previous quarter
Celldex Therapeutics's net income has decreased by 45% YoY and by 3.7% from the previous quarter
Celldex Therapeutics's equity has decreased by 24% YoY and by 6% from the previous quarter

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
46.48M
Market cap
$2.23B
Enterprise value
$2.19B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.42
Price to sales (P/S)
220.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
253.96
Earnings
Revenue
$8.62M
EBIT
-$66.97M
EBITDA
-$63.82M
Free cash flow
-$48.14M
Per share
EPS
-$1.7
Free cash flow per share
-$1.22
Book value per share
$4.6
Revenue per share
$0.22
TBVPS
$4.39
Balance sheet
Total assets
$204.55M
Total liabilities
$22.27M
Debt
$2.78M
Equity
$182.28M
Working capital
$153.12M
Liquidity
Debt to equity
0.02
Current ratio
11.57
Quick ratio
11.36
Net debt/EBITDA
0.64
Margins
EBITDA margin
-740.5%
Gross margin
100%
Net margin
-766.2%
Operating margin
-786.5%
Efficiency
Return on assets
-28.9%
Return on equity
-32.4%
Return on invested capital
-48%
Return on capital employed
-35.2%
Return on sales
-777.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
1.2%
1 week
5.92%
1 month
-13.13%
1 year
193.87%
YTD
173.74%
QTD
-11.17%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$8.62M
Gross profit
$8.62M
Operating income
-$67.78M
Net income
-$66.04M
Gross margin
100%
Net margin
-766.2%
Celldex Therapeutics's revenue has soared by 96% YoY and by 60% from the previous quarter
The company's gross profit has surged by 96% YoY and by 60% QoQ
Celldex Therapeutics's net income has decreased by 45% YoY and by 3.7% from the previous quarter
CLDX's operating margin is up by 41% since the previous quarter and by 38% year-on-year

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
10.42
P/S
220.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
253.96
CLDX's EPS is up by 34% YoY and by 9% from the previous quarter
The P/B is 140% higher than the last 4 quarters average of 4.3
Celldex Therapeutics's equity has decreased by 24% YoY and by 6% from the previous quarter
Celldex Therapeutics's revenue has soared by 96% YoY and by 60% from the previous quarter
CLDX's price to sales (P/S) is 73% higher than its last 4 quarters average of 126.1

Efficiency

How efficient is Celldex Therapeutics business performance
CLDX's ROS is up by 36% from the previous quarter and by 25% YoY
Celldex Therapeutics's ROIC has increased by 25% YoY but it has decreased by 7% from the previous quarter
The ROE has contracted by 11% from the previous quarter but it has grown by 8% YoY
The ROA is down by 10% QoQ

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
CLDX's quick ratio is down by 41% year-on-year but it is up by 8% since the previous quarter
The current ratio has decreased by 40% YoY but it has increased by 8% from the previous quarter
The debt is 98% lower than the equity
CLDX's debt to equity has surged by 100% year-on-year
Celldex Therapeutics's equity has decreased by 24% YoY and by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.